macimorelin

Description: Macimorelin (formerly known as AEZS-130 or EP-1572 or JMV1843; trade name: Macrilen) is a novel and potent synthetic small molecule growth hormone secretagogue receptor agonist. As a ghrelin agonist, it is orally active and stimulates the secretion of growth hormone (GH). As of December 2017, it became FDA-approved as a method to diagnose growth hormone deficiency. Traditionally, growth hormone deficiency was diagnosed via means of insulin tolerance test (IST) or glucagon stimulation test (GST). These two means are done parenterally, whereas Macrilen boasts an oral formulation for ease of administration for patients and providers.

References: Journal of Clinical Endocrinology & Metabolism. 2013, 98 (6): 2422.

Related CAS#:945212-59-9 (Macimorelin acetate)